These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25645089)

  • 41. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atypical squamous cells of undetermined significance in liquid-based cytologic specimens: results of reflex human papillomavirus testing and histologic follow-up in routine practice with comparison of interpretive and probabilistic reporting methods.
    Levi AW; Kelly DP; Rosenthal DL; Ronnett BM
    Cancer; 2003 Aug; 99(4):191-7. PubMed ID: 12925979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia.
    Kudoh A; Sato S; Itamochi H; Komatsu H; Nonaka M; Sato S; Chikumi J; Shimada M; Oishi T; Kigawa J; Harada T
    Int J Clin Oncol; 2016 Jun; 21(3):580-7. PubMed ID: 26614089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP).
    Duesing N; Schwarz J; Choschzick M; Jaenicke F; Gieseking F; Issa R; Mahner S; Woelber L
    Arch Gynecol Obstet; 2012 Dec; 286(6):1549-54. PubMed ID: 22865036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of HPV testing in the follow-up of women treated for cervical dysplasia.
    Ribaldone R; Boldorini R; Capuano A; Arrigoni S; Di Oto A; Surico N
    Arch Gynecol Obstet; 2010 Aug; 282(2):193-7. PubMed ID: 20012636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway.
    Budal EB; Haugland HK; Skar R; Maehle BO; Bjørge T; Vintermyr OK
    Cancer Med; 2014 Feb; 3(1):182-9. PubMed ID: 24403090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.
    Onuki M; Matsumoto K; Sakurai M; Ochi H; Minaguchi T; Satoh T; Yoshikawa H
    J Gynecol Oncol; 2016 Jan; 27(1):e3. PubMed ID: 26463429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
    Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
    J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Sand FL; Kjaer SK; Frederiksen K; Dehlendorff C
    Int J Cancer; 2020 Aug; 147(3):641-647. PubMed ID: 31648368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions.
    Smart OC; Sykes P; Macnab H; Jennings L
    Aust N Z J Obstet Gynaecol; 2010 Apr; 50(2):164-7. PubMed ID: 20522074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.
    Recio FO; Sahai Srivastava BI; Wong C; Hempling RE; Eltabbakh GH; Piver MS
    Eur J Gynaecol Oncol; 1998; 19(3):203-8. PubMed ID: 9641214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.